EMA Medicine safety communications
RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq: quality defect
Published by European Medicines Agency:
Summary
Quality defect
Medicine
RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): tocilizumab;emicizumab;trastuzumab;trastuzumab emtansine;rituximab;pertuzumab;trastuzumab;atezolizumab
- Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection;Hemophilia A;Stomach Neoplasms;Breast Neoplasms;Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell;Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Small Cell Lung Carcinoma
- ATC code: L04AC07;B02BX06;L01XC03;L01XC14;L01XC02;L01XY
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗